At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Annual Study of Safety and Immunogenicity of Influenza Virus Vaccine Fluzone® 2004-2005
In Brief
A Phase 4 clinical trial evaluating Fluzone®: Influenza virus vaccine 2004-2005 formulation for Influenza. Completed, enrolled 120 participants across 1 site.
Detailed Summary
To observe and to describe the safety during Days 0 to 21 following injection of the 2004-2005 formulation of the inactivated, split-virion influenza vaccine Fluzone® in subjects aged 18-59 years and subjects aged ≥ 60 years. To measure and to describe the immune response (antibodies to hemagglutinin) 21 days following injection of the 2004-2005 formulation of the inactivated, split-virion influenza vaccine Fluzone®, in subjects aged 18-59 years and subjects aged ≥ 60 years.
Study Details
Timeline
Interventions
0.5 mL, Intramuscular
0.5 mL, Intramuscular